Drug Profile

Research programme: mHTT targeted therapeutics - Arvinas

Latest Information Update: 12 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arvinas
Class Small molecules
Mechanism of Action Proteolysis

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Huntington's disease

Most Recent Events

12 Nov 2025 mHTT targeted therapeutics is still in preclinical trials for Huntington’s disease in USA (Arvinas pipeline; November 2025)
20 Oct 2022 Preclinical trials in Huntington's disease in USA (unspecified route) (Arvinas pipeline; October 2022)
14 Oct 2020 Research programme: mHTT targeted therapeutics - Arvinas is available for licensing as of 14 Oct 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com